Byondis B.v.

Hanke Lottie Matlung

Timo Kars Van Den Berg

Gijsbertus Franciscus Maria Verheijden

Gerard Rouwendal

Katarina Franke

Roland Jan Arends

The invention relates to antibodies against SIRP&#x3b1; that are suitable for use in anti-cancer therapy. The invention also relates to the use of the anti-SIRP&#x3b1; antibodies in the treatment of human solid tumours and haematological malignancies, optionally in combination with other anti-cancer therapies.

Anti-SIRP &#x3b1; antibodies

The present invention relates to antibodies against SIRP&#x3b1; that are suitable for use in anti-cancer therapy. The invention further relates to the use of the anti-SIRP&#x3b1; antibodies in the treatment of human solid tumours and haematological malignancies, optionally in combination with other anti-cancer therapeutics. The anti-SIRPalpha antibodies described are more specific than known anti-SIRPalpha antibodies, whereas they show excellent affinity for both SIRPalpha1 and SIRPalphaBIT. In one embodiment the anti-SIRPalpha antibodies do not bind to SIRPgamma. In a second embodiment, the anti-SIRPalpha antibodies do not bind to SIRPgamma and do not bind to SIRPbeta1v1. In a third embodiment, the anti-SIRPalpha antibodies do not bind to SIRPgamma and do not bind to SIRPeta1v2. In a fourth embodiment, the anti-SIRPalpha antibodies do not bind to SIRPbeta1v1.

Growing community of inventors

Amsterdam, Netherlands

Hanke Lottie Matlung